NEW YORK ( TheStreet) -- It's now been two full quarters since healthcare conglomerate Abbott Laboratories (ABT) effectively separated itself from its drug business -- spinning off that segment into a new entity called AbbVie (ABBV).
The spin-off, which was originally announced in late 2011, was a long-anticipated move, for which Abbott investors cheered. It came with plenty of expectations that the remaining portion of Abbott, which consists of the devices business, would post stronger growth results. But since the separation took effect in January of this year, questions have been raised as to which of the two companies presents the better value.
Shares of AbbVie, which have soared more than 30% on the year, have been one of the best performers within the sector. Abbott, meanwhile, has posted gains of 16%. It's not a terrible performance, but the stock has lagged behind Johnson & Johnson (JNJ) and Medtronic (MDT). Although second-quarter earnings results were better than expected, I didn't see enough to buy shares of Abbott today with my own money.
As with the April quarter, revenue growth, which registered at just 2% year over year, was another struggle. Even when adjusting for currency exchange rates, which pushes Abbott's growth rate to 4%, the company still missed estimates. By contrast, it pales in comparison to Johnson & Johnson, which recently posted year-over-year growth of 10%.As with Johnson & Johnson, which has come to rely heavily on its drugs business, it is Abbott's nutrition business, which now accounts for 31% of the company's revenue, that continues to do all of the heavily lifting. Nutrition was up 8% year-over year. It's starting to appear as if Abbott's international expansion plans are paying dividends. Management said the strong performance was due to geographic development programs that it projected would have spurred these type of results. In that regard, investors should be encouraged that revenue in both pediatric and adult products are growing better-than-expected at a high-single-digit pace. To what degree this performance can continue remains to be seen. But for now, I'm not willing to bet against management's plan to achieve 20% operating margin in nutrition over the next two years. Unfortunately, though, this is the extent of the positives that I could draw from the quarter. Outside of the 8% increase in the diagnostics business, I was disappointed by Abbott's performance in its other businesses.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV